We focus on five social themes.
TNO cooperates with companies, the public sector and other organisations, to apply our knowledge and expertise with and for others.
We develop knowledge not for its own sake, but for practical application.
TNO offers you the chance to do groundbreaking work and help customers and society with innovative, practical and smart solutions.
On our TNOTIME platform you can find blogs, interviews and background stories. Discover the field of TNO captured in photographs, animations, video and text. Share interesting articles and powerful infographics, or download whitepapers.
Organ function-on-a-chip models are in vitro models that closely resemble the structural tissue arrangements and functional complexity of living organs by using human (stem)cells cultured on microfluidic chips. TNO will generate, optimize and validate sophisticated generations of human in vitro 'organ function-on-a-chip' models, to satisfy the high but unmet need of the pharmaceutical industry for better predictive preclinical models that represent the human situation.
Organ function-on-a-chip models are in vitro models that closely resemble the structural tissue arrangements and functional complexity of living organs by using human (stem)cells cultured on microfluidic chips.
Better preclinical models that represent the human situation are needed for better prediction of success or failure of compounds in the clinical drug development phase. These predictive models would serve the unmet need of the pharmaceutical industry, and will also find applications in nutrition industry, which increasingly uses pharmaceutical research models for testing efficacy of compounds and ingredients. Organ function-on-a-chip models provide a promising animal-free approach to solve this issue.
TNO has unique knowledge and technologies in house to significantly improve and speed up the model development, validation and application of 'organ function-on-a-chip' technology. These technologies and knowledge include in vitro (cells, tissues), in vivo (humanized animal models, human studies) and in silico (systems biology, PBPK modeling) systems as well as various analytical tools (-omics, accelerator mass spectrometry, imaging) which are highly relevant for the generation, validation and application of organ function-on-a-chip technology. Furthermore, TNO harbors technologies such as microfluidics and optical imaging which will be highly relevant for the automation of screening tools and development of online readout systems. Also the 3D (bio)printing expertise at TNO could be very useful to develop more sophisticated chips by printing specific scaffolds or even printing cells in 3D to form a more physiological structured organ model. By combining these technologies we will unlock the full potential of the expertise present at TNO. We aim to collaborate with both the pharmaceutical industry and technology providers to establish an ecosystem that has full potential of developing relevant organ function-on-a-chip systems for various applications.
Our breakthrough technology will be better predictive and time reducing screening platforms, which will improve and shorten the preclinical drug development process. TNO chose to focus on liver-, gut- and lung function-on-a-chip. In all three cases the first step will be to generate relatively simple, cellbased medium throughput in vitro models with relevant readouts, which can as such already be used by industrial partners.
TNO aims to develop an in vitro model for multifactorial liver disease (with a focus on NASH) which can be used to study:
TNO aims to develop an in vitro model of the intestine that mimics the structural, absorptive, transport and pathophysiological properties of the human gut (preferably in combination with its microbiota) in order to study:
TNO aims to develop a portable system that measures the effect of air pollution on human health and helps to identify situations of risk. Our in-house knowledge and expertise on (online) read-out technology will be used to measure physiological parameters, including CO levels as a measurement for viability of (lung)cells.
Download the whitepaper
Stay up to date with our latest news, activities and vacancies
We use anonymous cookies to enhance the use of our site.